PDF Cover

Neurovascular Devices Market

The market for Neurovascular Devices was estimated at $3.9 billion in 2025; it is anticipated to increase to $6.0 billion by 2030, with projections indicating growth to around $9.2 billion by 2035.

Report ID:DS1801076
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Neurovascular Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Neurovascular Devices Market Outlook

Revenue, 2025

$3.9B

Forecast, 2035

$9.2B

CAGR, 2026 - 2035

9.1%

The Neurovascular Devices industry revenue is expected to be around $3.9 billion in 2026 and expected to showcase growth with 9.1% CAGR between 2026 and 2035. A growing emphasis on neurovascular devices points to the growing value these have for healthcare, as a result of their cost and clinical benefits. They are being used increasingly by neurocentres and hospitals in stroke treatment, reducing the need for long term care and cutting the numbers of people who die from stroke. Applications with significant demand are cerebral aneurysm and ischaemic stroke, these together accounting for 77.2% of the adoption of the technology in question. This is due to the necessity for long term cerebral aneurysm repair and the need for quick treatment of ischaemic stroke. The neurovascular devices market was dominated by embolization devices in 2025, when the latter sold approximately 1.44 billion dollars. Advances in the development of coils, liquid embolic agents and additional treatment tools are factors which have contributed to higher success rates in procedures and increased safety. The demand in endovascular neurosurgery devices is being driven by factors including growth of minimally invasive neurovascular procedures, expanding access to neurovascular centres in developing countries and the associated payment for the treatments.

With their range of neurovascular products they offer medical professionals the high degree of flexibility, precision, radiodense properties and biocompatibility they require for safe neurosurgery. Neurovascular products include catheters, stent retrievers, flow diverters, balloon catheters, microcatheters and guidewires. These are primarily used for the treatment of strokes, cerebral aneurysm repair and the management of arteriovenous malformations and narrowed blood vessels within the brain. The demand for newer technology is driven by a number of factors including improved stent designs which are stronger yet thinner, improved surface coatings which reduce the risk of the formation of blood clots and enhanced imaging and navigation tools that help doctors with complex procedures. There has been a significant trend towards the earlier identification of stroke sufferers, utilisation of stroke management systems which involve a set of established procedures and an expansion in the application of procedures involving minimal invasion to address vascular issues within the brain.

Neurovascular Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Neurovascular Devices Market Outlook

Market Key Insights

  • The Neurovascular Devices market is projected to grow from $3.9 billion in 2025 to $9.2 billion in 2035. This represents a CAGR of 9.1%, reflecting rising demand across Cerebral Aneurysm, Ischemic Stroke, and Carotid Artery Stenosis.

  • Companies of the calibre of Medtronic, Johnson and Johnson and Stryker are active in this medical industry, and are instrumental in the markets competitive dynamics.

  • The US and German markets are likely to lead the way within the neurovascular devices industry, with growth over the forecast period predicted to be somewhere between 6.8% and 9.8 %.

  • The countries with the highest growth rates are expected to be emerging markets such as those in India, Brazil and Mexico, where growth is expected to be between 8.9% and 11.6% CAGR.

  • The expected rise in adoption of neurovascular devices is expected to bring about $219 million in growth to the neurovascular devices market by the year 2030.

  • Neurovascular devices are forecast to expand by 5.4 billion dollars between 2035 and 2025. This growth will be driven mainly by the carotid artery stenosis and ischemic stroke applications.

  • The incidence of neurovascular diseases is rising. Due to this trend and technological progress in the medical industry, the neurovascular devices market is expected to rise by 143% by 2034 relative to 2024.

neurovascular devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Neurovascular Devices - Country Share Analysis

Opportunities in the Neurovascular Devices

In North America and China, AI enabled and integrated stroke networks that are comprehensive and that link telemedicine, emergency services and stroke centres are being built. This has enabled Neurovascular devices to be used on a much larger scale. The neurointerventional devices sector encompasses stenting systems, embolization devices, neurothrombectomy devices and others. It is also predicted that neurointerventional devices in the others category will rise to $0.62 billion by 2030, from $0.43 billion this year, at a compound annual growth rate of 7.25%.Companies that incorporate image analytics, telehealth services and remote support tools into acute ischemic stroke treatment will pick up market share by using evidence based endovascular therapy methods.

Growth Opportunities in North America and Asia Pacific

The North American neurovascular devices industry is currently driven by well established stroke systems of care. The major segment in the industry is that for the treatment of ischaemic stroke due to high volumes of procedures required in endovascular therapy. A lesser but significant part of the market is the treatment of cerebral aneurysms. The main regional opportunities will be in next generation embolectomy catheters and image guided neurovascular stents and flow diverters. These are designed to enable quicker door to recanalisation treatments. This is linked to the integration of neurocritical care with neurosurgery. The competitive landscape is very competitive with big pharmaceutical companies utilising their strong relationships with key opinion leaders and their premium product portfolios. Regional companies however, have responded by improving the efficiency of their operations and ensuring that their equipment is compatible with hybrid operating theatres. The key drivers of growth within this sector are the high neurologist and neurointerventionist density, the broad access to the comprehensive stroke centres, the reimbursement of complex neurointerventions and the use of AI enabled imaging to increase the population that can be treated and thereby increase demand.
Asia Pacific is expected to see a rapid expansion of its stroke care infrastructure. This expansion comes at a time when the disease is becoming more prevalent in the region. The prevalence of stroke is significantly higher in Asia Pacific than it is in North America. These opportunities exist within portfolios for endovascular treatments which are both cost effective and adaptable to the needs of the hospital. This includes products such as embolectomy catheters and embolization systems as well as products which require training to achieve higher success rates in neurology centres. The market is being influenced by a dynamic interplay between local firms which are growing rapidly and the major global manufacturers, both of which are putting a lot of emphasis on localized production. In order to enter the market quicker, these manufacturers are aligning themselves with the local regulatory requirements. This is also accompanied by a concentration on value engineered flow diverters and neurovascular stents. Investments in stroke units are being driven by the major healthcare systems in the Asia Pacific region due to public and private investment increases, an increase in the use of minimally invasive neurosurgery, the support for urban hubs advanced stroke care from the government and the switch to catheter based procedures from open neurosurgery.

Market Dynamics and Supply Chain

01

Driver: Integration of Endovascular Technologies and Rising Neurovascular Disease Burden

The neurovascular devices market is also strongly driven by advancements in minimally invasive endovascular technologies and the increasing prevalence of neurovascular disorders such as stroke and aneurysms. Innovations in device design like flow diverters, stent retrievers, embolic coils, and neurovascular catheters improve procedural safety, precision, and patient outcomes, supporting wider adoption in hospitals and interventional centers. These less invasive options reduce recovery times and complications, making them preferable over open surgical approaches. At the same time, the growing global incidence of stroke, largely tied to aging populations and cardiovascular risk factors, boosts demand for effective therapeutic solutions and increases procedural volumes, directly expanding the market for neurovascular devices worldwide.
A key driver for neurovascular devices is also the expansion of favorable reimbursement frameworks and healthcare infrastructure upgrades in developed regions. Reimbursement programs, especially in North America and Europe, cover a significant portion of procedural and device costs, making advanced neurovascular interventions more accessible to patients and attractive for healthcare providers to adopt. Enhanced financial support increases device utilization across public and private hospitals, reducing cost barriers and accelerating market growth as treatments for stroke and related conditions become more economically viable. 
02

Restraint: High Procedure Costs and Reimbursement Variability Limit Adoption Rates and Revenue Growth

One key restraint for neurovascular devices is the high cost of procedures combined with inconsistent reimbursement policies across regions. Advanced devices like flow diverters and stent retrievers are expensive, and in markets with limited or unclear insurance coverage, hospitals may delay investment. This reduces procedure volumes, constrains revenue growth, and slows broader market adoption, particularly in emerging economies where healthcare budgets and reimbursement frameworks are less robust.
03

Opportunity: Rising acute ischemic stroke burden among aging populations in Asia-Pacific driving demand for advanced Neurovascular Devices and Elective minimally invasive cerebral aneurysm repair in Western Europe accelerating adoption of premium embolization Neurovascular Devices

In the Asia Pacific region, there has been a rapid urbanisation with a resultant shift in lifestyle which is resulting in a rise in acute ischemic stroke cases. This rise is more notable in India and China where there is a scarcity of preventive measures. The market for neurovascular devices is currently not only well explored and has an increasing demand, specifically for neurothrombectomy devices. These neurothrombectomy devices have the highest rate of growth among all neurovascular devices. They are expected to grow at a CAGR of 11.3% to reach $1.89 billion by 2030 from $1.11 billion in 2025. Many medical centres are developing their endovascular therapy departments and their catheter based treatment options. This is providing a promising market for the producers of medical equipment who are able to provide cost effective treatment options for stroke sufferers and who have a reimbursement friendly business model.
Demand for elective cerebral aneurysm surgery in Western Europe is moving from traditional open neurosurgery towards the use of the minimally invasive form of neurosurgery. This trend is promoting the sales of high end neurovascular devices. These devices are used to obtain more durable cosmetic results. In 2025 the market for Embolization Devices was valued at 1.44 billion dollars and forecasts predict it will grow to 2.17 billion by the year 2030 with a compound annual growth rate of 8.6%.This growth rate exceeds that of Stenting Systems. Advances in stroke care are being seen in high volume stroke centers where they employ the latest technology, including stents, flow diverters and next generation coils. This technology is paired with enhanced navigation capabilities and more efficient inventory systems to treat complex aneurisms.
04

Challenge: Stringent Regulatory Approvals and Clinical Evidence Requirements Delay Product Launches and Market Access

Another major restraint is the rigorous and time‑intensive regulatory approval process, coupled with the need for extensive clinical data to support safety and efficacy. Neurovascular devices often require complex trials and lengthy evaluations by agencies like the FDA and EMA. These hurdles delay product launches, increase development costs, and can deter smaller innovators, slowing competitive dynamics and limiting the pace at which new technologies reach clinical use.

Supply Chain Landscape

1

Catheters & Stents Sourcing

Integer HoldingsLake Region Medical
2

Neurovascular Devices Manufacturing

Medtronic plcStryker
3

Interventional Neuroradiology Distribution

Cardinal HealthOwens & Minor
4

Stroke Care End-Users

HospitalsAmbulatory Surgical CentersSpecialty Neuroscience Clinics
Neurovascular Devices - Supply Chain

Use Cases of Neurovascular Devices in Cerebral Aneurysm & Carotid Artery Stenosis

Cerebral Aneurysm : Neurovascular devices play a crucial role in cerebral aneurysm treatment by enabling minimally invasive endovascular therapy that reduces rupture risk and improves patient outcomes. Embolic coils and flow diverter stents are most commonly used by interventional neuroradiologists and neurosurgeons to occlude aneurysm sacs or divert blood flow away from weak vessel walls, promoting safe thrombosis and healing. Leading market players such as Medtronic, Stryker, Johnson & Johnson, Boston Scientific, and Terumo/MicroVention offer advanced coil and flow diversion technologies with strong clinical evidence, global regulatory approvals, and extensive training programs, strengthening their positions in hospitals and specialty centers focused on neurovascular care.
Ischemic Stroke : Neurovascular devices play a critical role in ischemic stroke treatment by enabling rapid restoration of blood flow through mechanical clot removal. Stent retrievers and aspiration catheters are the most commonly used devices in hospitals and neurointerventional centers to capture and extract thrombi from cerebral arteries, significantly improving neurological outcomes when deployed within therapeutic windows. Leading market players such as Medtronic, Stryker, Penumbra, Boston Scientific, and Terumo Corporation dominate this application with innovative device portfolios, strong clinical evidence, and widespread adoption in acute stroke care protocols, enhancing patient survival and functional recovery rates.
Carotid Artery Stenosis : Carotid artery stenosis treatment often relies on neurovascular devices such as carotid artery stents, embolic protection devices, and balloon catheters, which are widely used in hospitals and interventional centers to restore blood flow and prevent ischemic stroke. Carotid stents provide scaffold support to narrowed arteries, while embolic protection systems help capture debris during procedures, reducing complication risks. Top players like Medtronic, Abbott, Boston Scientific, and Terumo are strong in this segment with advanced stenting technologies, robust clinical evidence, and global distribution networks that enhance patient outcomes and drive adoption in vascular intervention practices.

Recent Developments

Recent developments in neurovascular devices show sustained momentum in minimally invasive treatments and advanced regulatory approvals, driven by rising stroke prevalence and imaging‑guided intervention preferences. Recently, Terumo Neuro’s Dual‑Layer Micromesh Carotid Stent System received FDA premarket approval, expanding therapeutic options for carotid artery stenosis and strengthening device portfolios in the U.S. market. Q2 2024 also saw Medtronic secure FDA approval for its Pipeline Flex Embolization Device with Shield Technology, enhancing aneurysm care with improved biocompatibility and clinical outcomes. These advancements reflect broader trends toward precision endovascular therapy, stents and embolization systems, and integration with high‑resolution imaging, boosting hospital adoption and procedural volumes.

June 2025 : Terumo Neuro announced the U.S. commercial availability of its SOFIA 88 Neurovascular Support Catheter, an advanced large‑bore catheter designed for improved stroke intervention performance and procedural flexibility, expanding its stroke treatment portfolio and reinforcing market presence.
February 2025 : Johnson & Johnson MedTech introduced the CEREGLIDE 92 Catheter System, a next‑generation catheter featuring improved delivery technology to support acute ischemic stroke treatments, strengthening its neurointerventional product lineup.

Impact of Industry Transitions on the Neurovascular Devices Market

As a core segment of the Medical Device industry, the Neurovascular Devices market develops in line with broader industry shifts. Over recent years, transitions such as Increased Adoption of Neurovascular Devices and Integration of AI, Imaging, and Robotic Assistance have redefined priorities across the Medical Device sector, influencing how the Neurovascular Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Increased Adoption of Neurovascular Devices

The main driver of the increase in neurovascular device sales is accelerating. This factor will add $219 million to the industry by the year 2030, as it becomes more financially viable for hospitals to make use of neurovascular intervention technology. The increasing need for cerebral aneurysm treatments and ischemic stroke therapies has prompted healthcare facilities to upgrade their interventional neuroradiology equipment and systems. In addition to increasing the number of procedures carried out using thrombectomy devices and coils for embolisation, it is also driving the demand for new catheter based methods of treating strokes which provide better outcomes. Companies that are at the forefront of innovation in neurovascular devices, who also provide a diverse range of products and training for neurologists, will be in the best position to take advantage of the neurovascular devices market and protect their market position in the long term. This represents a $219 million market opportunity.
02

Integration of AI, Imaging, and Robotic Assistance

Another major transition is the integration of artificial intelligence, advanced imaging, and robotic-assisted navigation into neurovascular procedures. AI-powered imaging aids in vessel segmentation, procedural planning, and real-time decision support, while robotic platforms enhance precision in catheter navigation. This transition impacts adjacent industries such as medical imaging, digital health, and surgical robotics, enabling higher procedure accuracy, reducing operator dependency, and improving patient outcomes. Hospitals adopting these integrated systems gain competitive advantage by offering safer, more efficient treatments, influencing investment patterns in neurovascular and interventional care infrastructure.